Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.

Type2 Diabetes Clinical Trial

Official title:

Evaluation of Using a Nanotechnology Structured Water Magnalife® to Achieve Controlled Blood Glucose Level in Type 2 Diabetic Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04082351
• Other study ID #: USulaimani
• Status: Completed
• Phase: N/A
• Start date: July 3, 2016
• Est. completion date: February 16, 2018

Study information

• Verified date: September 2019
• Source: University of Sulaimani
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 2 DM is due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical, and physical properties of water molecules and improve the bioavailability of this nano-water. Objective: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with type 2 diabetes mellitus.

Description:

This is a blind randomized control trial, according to CONSORT guidelines for randomization, "Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups.", that included 387 patients with Type 2 diabetes mellitus in Diabetes Care Center, Sulaymaniyah, Kurdistan region from July 2016 till February 2018. A total of 387 patients with type 2 diabetes who were patients in this center and agreed to participate in this clinical trial were included in this study.

In group A, patients were given nanotechnology structured water Magnalife® and in group B they were given ordinary bottled drinking water as a control . The bottles were unlabeled so that the patients did not know which water they were drinking. Then they were asked to eat their usual food and to drink their usual drinks, also they could drink water ad libitum after drinking the daily doses, and to have the same physical activities that they used to do in their usual daily life. They were instructed to take their medications as usual, and were told to come to test their blood sugar level at the end of the third month to get the HbA1c tested at the end of the three months of drinking the water.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 387
• Est. completion date: February 16, 2018
• Est. primary completion date: February 16, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Type 2 diabetic patients

Exclusion Criteria:

• Malignancy

• Steroids

• Immunotherapy

• Chemotherapy

• Radiotherapy

• Chronic infections

• Drugs that antagonize or synergies insulin effects

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type2 Diabetes

Intervention

Dietary Supplement:
• Nanotechnology structured water ( Magnalife)
Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
• ordinary water
Ordinary bottled water

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ALI KAMAL M. SAMI

References & Publications (1)

Sami AKM, Amin KH, Kurmanji MT. The Novel Use of Nanotechnology Structured Water Magnalife to Control Blood Glucose Level in Type 2 Diabetic Patients. Diabetes. 2018;67(Supplement 1):1155.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c	measurement of HbA1c	three months